Wednesday, February 10, 2010, 6:18am EST - Canadian Markets open in 3 hours and 12 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Ariad Pharmaceuticals Inc. (ARIA)

On Feb 9: 2.35 USD   0.00 (0.00%)  
MORE ON ARIA
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
ARIAD Pharmaceuticals, Inc. (NGM:ARIA) Delayed quote dataEdit
Last Trade: 2.35 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 2.35
Open: N/A
Bid: 1.51 x 100
Ask: 2.88 x 100
1y Target Est: 5.00
Day's Range: N/A - N/A
52wk Range: 0.97 - 3.48
Volume: 0
Avg Vol (3m): 1,958,730
Market Cap: 256.05M
P/E (ttm): N/A
EPS (ttm): -0.94
Div & Yield: N/A (N/A%)
Ariad Pharmaceuticals Inc. (ARIA)
1d  5d  3m  6m  1y  2y  5y  max 
 Add ARIA to Portfolio   Download Data

HEADLINES
ARIAD to Present at the 12th Annual BIO CEO & Investor Conference
Business Wire (Thu, Jan 28)
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
EDGAR Online (Fri, Jan 22)
ARIAD to Present at the 28th Annual J.P. Morgan Healthcare Conference
Business Wire (Mon, Jan 4)
Top Ten '09 Clone Portfolios
at Seeking Alpha (Sun, Jan 3)
5 Cold Stocks Heating Up
at Motley Fool (Mon, Dec 28)
This Year's Upside Crash & 3 PowerRatings Stocks
TradingMarkets.com (Mon, Dec 21)
Friday Options Update: SVNT, JBLU, ROST, RVSN, MRVL, RYL, ARIA, WLP
at Seeking Alpha (Fri, Dec 18)
Friday Options Update: MRVL, RYL, ARIA, WLP
at Seeking Alpha (Fri, Dec 18)
Ariad rounds out phase 3 cancer study
at bizjournals.com (Fri, Dec 18)
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Thu, Dec 17)
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
Business Wire (Thu, Dec 17)
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue, Dec 15)
ARIAD Announces Updated Data from Clinical Trial of Its Investigational mTOR Inhibitor, Ridaforolimus, In Combination with Trastuzumab
Business Wire (Mon, Dec 14)
More Headlines for ARIA...

ANALYST
EPS Est (next year) (Dec-09) : -0.84
EPS Est (in 2 years) (Dec-10) : -0.63
Avg Rec (current)*: 1.4
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer in the United States and Europe.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News Canadian Indices